The effect of a modified fragment of neuropeptide Y on spatial memory and learning in the Morris water maze




modified fragment of neuropeptide Y, the Morris water maze, spatial memory, learning


Neuropeptide Y (NPY) is a biologically active neuropeptide that is responsible for a large list of physiological processes. We propose a short modified fragment of NPY that should at least partially have a spectrum of biological activity of the original peptide. The compound was named nonapeptide NP9.

The aim of our study was to investigate the ability of the modified fragment of NPY to influence spatial memory and learning.

Materials and methods: the study was performed on 24 one-year-old random-bred female rats weight 220–250 g. The animals were divided into 3 groups of 8 rats each: treated with a solvent (0.9 % NaCl), a solution of peptide NP9 0.02 mg/kg and the drug “Semax” 0.1 mg/kg. All drugs were administered intranasally. The study of the effect of the peptide NP9 on spatial memory and learning ability was performed in the psychopharmacological test the Morris water maze. Navigation parameters were analyzed using Noldus EthoVision XT 14 video tracking software. The escape latency, the distance moved, the average velocity and the meander were recorded. An inter-quadrant analysis of rat behavior was also performed, for which the frequency of appearance and time spent in certain quadrants were recorded.

Results: nonapeptide NP9 in the Morris water maze test demonstrated the ability to accelerate the time to find a hidden platform, reduce the distance traveled, meander, and optimize the search strategy.

Conclusions: NP9 peptide has demonstrated the ability to positively influence learning and spatial memory. The improvement in cognitive performance of animals administered with the peptide NP9 was no less than that of the reference nootropic drug Semax. These results substantiate the feasibility of further research with the aim of pharmaceutical development of a new nootropic drug

Author Biographies

Ihnat Havrylov, National University of Pharmacy

Department of Pharmacology and Pharmacotherapy

Sergey Shtrygol’, National University of Pharmacy

Doctor of Medical Science, Professor

Department of Pharmacology and Pharmacotherapy

Dmytryi Kavraiskyi, Bogomolets National Medical University

PhD, Assistant

Department of Pharmacy Organization and Economics


  1. Vos, T., Allen, C., Arora, M., Barber, R. M., Bhutta, Z. A., Brown, A. et. al. (2016). Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet, 388 (10053), 1545–1602. doi:
  2. Global Trends 2019: Forced Displacement in 2019 (2019). UNHCR Flagship Reports. Available at:
  3. Migrant populations, including children, at higher risk of mental health disorders (2017). World Health Organization. Available at: from,-including-children,-at-higher-risk-of-mental-health-disorders
  4. Alcântara, C. B. de, Capistrano, F. C., Czarnobay, J., Ferreira, A. C. Z., Brusamarello, T., Maftum, M. A. (2018). Drug therapy for people with mental disorders in the view of nursing professionals. Escola Anna Nery, 22 (2). doi:
  5. Zane, D., Feldman, P. L., Sawyer, T., Sobol, Z., Hawes, J. (2020). Development and Regulatory Challenges for Peptide Therapeutics. International Journal of Toxicology, 40 (2), 108–124. doi:
  6. Quinn, T. J. (2019). In people with vascular dementia, does cerebrolysin improve outcomes compared with placebo? Cochrane Clinical Answers. doi:
  7. Khavinson, V. K. (2020). Peptide medicines: past, present, future. Clinical Medicine, 98 (3), 165–177. doi:
  8. Yi, M., Li, H., Wu, Z., Yan, J., Liu, Q., Ou, C., Chen, M. (2017). A Promising Therapeutic Target for Metabolic Diseases: Neuropeptide Y Receptors in Humans. Cellular Physiology and Biochemistry, 45 (1), 88–107. doi:
  9. Méndez-Couz, M., Manahan-Vaughan, D., Silva, A. P., González-Pardo, H., Arias, J. L., Conejo, N. M. (2021). Metaplastic contribution of neuropeptide Y receptors to spatial memory acquisition. Behavioural Brain Research, 396. doi:
  10. Gøtzsche, C. R., Woldbye, D. P. D. (2016). The role of NPY in learning and memory. Neuropeptides, 55, 79–89. doi:
  11. Lach, G., de Lima, T. C. M. (2013). Role of NPY Y1 receptor on acquisition, consolidation and extinction on contextual fear conditioning: Dissociation between anxiety, locomotion and non-emotional memory behavior. Neurobiology of Learning and Memory, 103, 26–33. doi:
  12. Kornhuber, J., Zoicas, I. (2019). Neuropeptide Y reduces expression of social fear via simultaneous activation of Y1 and Y2 receptors. Journal of Psychopharmacology, 33 (12), 1533–1539. doi:
  13. Kornhuber, J., Zoicas, I. (2017). Neuropeptide Y prolongs non-social memory and differentially affects acquisition, consolidation, and retrieval of non-social and social memory in male mice. Scientific Reports, 7 (1). doi:
  14. Rangani, R., Upadhya, M., Nakhate, K., Kokare, D., Subhedar, N. (2012). Nicotine evoked improvement in learning and memory is mediated through NPY Y1 receptors in rat model of Alzheimer’s disease. Peptides, 33 (2), 317–328. doi:
  15. Flood, J. F., Hernandez, E. N., Morley, J. E. (1987). Modulation of memory processing by neuropeptide Y. Brain Research, 421 (1-2), 280–290. doi:
  16. Bouchard, P., Maurice, T., St-Pierre, S., Privat, A., Quirion, R. (1997). Neuropeptide Y and the Calcitonin Gene-related Peptide Attenuate Learning Impairments Induced by MK-801 via a Sigma Receptor-related mechanism. European Journal of Neuroscience, 9 (10), 2142–2151. doi:
  17. Brothers, S. P., Wahlestedt, C. (2010). Therapeutic potential of neuropeptide Y (NPY) receptor ligands. EMBO Molecular Medicine, 2 (11), 429–439. doi:
  18. Pedragosa-Badia, X., Stichel, J., Beck-Sickinger, A. G. (2013). Neuropeptide Y receptors: how to get subtype selectivity. Frontiers in Endocrinology, 4. doi:
  19. Di, L. (2014). Strategic Approaches to Optimizing Peptide ADME Properties. The AAPS Journal, 17 (1), 134–143. doi:
  20. Zagayko, A. L., Havrylov, I. O., Lytkin, D. V. (2019). The study of the effect of the low molecular analog of neuropeptide Y on behavioral reactions in rats. Clinical Pharmacy, 23 (4), 30–36. doi:
  21. Havrylov, I. O., Shtrygol, S. Yu. (2021). Investigation of the effect of a modified fragment of neuropeptide Y on memory phases and extrapolation escape of animals. Česká a Slovenská Farmacie, 70 (3), 91–99. doi:
  22. Sabban, E. L., Alaluf, L. G., Serova, L. I. (2016). Potential of neuropeptide Y for preventing or treating post-traumatic stress disorder. Neuropeptides, 56, 19–24. doi:
  23. Meredith, M. E., Salameh, T. S., Banks, W. A. (2015). Intranasal Delivery of Proteins and Peptides in the Treatment of Neurodegenerative Diseases. The AAPS Journal, 17 (4), 780–787. doi:
  24. Mironov, A. V. (2012). Rukovodstvo po provedeniiu doklinicheskikh issledovanii lekarstvennykh veschestv. Part. 1. Moscow: Grif i K, 944.
  25. Garthe, A., Kempermann, G. (2013). An old test for new neurons: refining the Morris water maze to study the functional relevance of adult hippocampal neurogenesis. Frontiers in Neuroscience, 7. doi:
  26. Nunez, J. (2008). Morris Water Maze Experiment. Journal of Visualized Experiments, 19. doi:
  27. Koroleva, S. V., Myasoedov, N. F. (2018). Semax as a Universal Drug for Therapy and Research. Biology Bulletin, 45 (6), 589–600. doi:
  28. Kallupi, M., Vendruscolo, L. F., Carmichael, C. Y., George, O., Koob, G. F., Gilpin, N. W. (2013). Neuropeptide Y Y2R blockade in the central amygdala reduces anxiety-like behavior but not alcohol drinking in alcohol-dependent rats. Addiction Biology, 19 (5), 755–757. doi:




How to Cite

Havrylov, I., Shtrygol’, S., & Kavraiskyi, D. (2022). The effect of a modified fragment of neuropeptide Y on spatial memory and learning in the Morris water maze. ScienceRise: Pharmaceutical Science, (1(35), 22–27.



Pharmaceutical Science